Release Date: 24/08/20 08:55 Summary: FY20 Full Year Results - Investor Presentation Price Sensitive: Yes Download Document 2.2MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%